🇺🇸 FDA

Intelligence Platform

Patents

Browse 302 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8742129

Crystalline forms of febuxostat

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8722722

Raltegravir salts and crystalline forms thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 13 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8709433

Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8691872

Dispersions of rasagiline citrate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8673322

Crystals of laquinimod sodium, and process for the manufacture thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8663703

Drug microparticles, processes of preparing them and a drug delivery vehicle comprising th

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8653060

Formulations of 6-mercaptopurine

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8647646

Crystals of laquinimod sodium, and process for the manufacture thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8614252

Crystalline solid rasagiline base

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8598203

Treatment of Crohn's disease with laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8597666

Compressed solid dosage form manufacturing process well-suited for use with drugs of low a

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8592442

Nilotinib HCl crystalline forms

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8580819

Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carbo

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8569379

Use of rasagiline for the treatment of olfactory dysfunction

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8545885

Stable laquinimod preparations

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8541373

BChE albumin fusions for the treatment of cocaine abuse

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8536149

TRPM-2 antisense therapy

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Sep 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8501766

Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8487097

Reference standard for characterization of rosuvastatin

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jul 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8470344

Aqueous dispersions and solutions of difficult to dissolve materials and methods of their

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 25 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8414920

Pharmaceutical composition containing irbesartan

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8415314

Methods for treating multiple sclerosis using antisense oligonucleotides

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8414918

Stable imatinib compositions

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8410288

Polymorphs of Saxagliptin hydrochloride and processes for preparing them

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted